標(biāo)題: Titlebook: New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia; W. Hiddemann,R. Mertelsmann Conference proceedings 1990 Springer-V [打印本頁] 作者: Awkward 時(shí)間: 2025-3-21 17:27
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia影響因子(影響力)
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia影響因子(影響力)學(xué)科排名
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia網(wǎng)絡(luò)公開度
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia被引頻次
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia被引頻次學(xué)科排名
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia年度引用
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia年度引用學(xué)科排名
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia讀者反饋
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia讀者反饋學(xué)科排名
作者: 使激動(dòng) 時(shí)間: 2025-3-21 20:52 作者: Debate 時(shí)間: 2025-3-22 00:41 作者: 調(diào)整校對(duì) 時(shí)間: 2025-3-22 07:42
Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute or 5 days) and intermediate-dose cytosine arabinoside (Ara-C 1 g/m. twice daily for 4 days). Most patients had received previous therapy with high- or intermediate-dose Ara-C plus mitoxantrone (HAM, IAM) and TAD (6-thioguanine, standard-dose cytosine arabinoside, and daunorubicin). Four patients had作者: 極大的痛苦 時(shí)間: 2025-3-22 12:13 作者: 使成波狀 時(shí)間: 2025-3-22 13:22 作者: FRAUD 時(shí)間: 2025-3-22 20:01 作者: 約會(huì) 時(shí)間: 2025-3-22 23:41 作者: 有惡臭 時(shí)間: 2025-3-23 04:16 作者: Flagging 時(shí)間: 2025-3-23 07:54 作者: etidronate 時(shí)間: 2025-3-23 12:57 作者: 果核 時(shí)間: 2025-3-23 17:35 作者: 空氣傳播 時(shí)間: 2025-3-23 18:33 作者: Aura231 時(shí)間: 2025-3-23 22:39
D. Lutz,O. Krieger,H. Kasparu,E. Fiedleres of devices, and process them e ciently. These include homeland security - plications, sensor/pervasive computing applications, various kinds of mo- toring applications, and even traditional applications belonging to nancial, computer network management, and telecommunication domains. These - plic作者: orthopedist 時(shí)間: 2025-3-24 05:24
J. M. Rowe,A. Y. C. Chang,J. M. Bennettes needs beyond the stream processing model.Discusses in detIn recent years, a new class of applications has come to the forefront { p- marily due to the advancement in our ability to collect data from multitudes of devices, and process them e ciently. These include homeland security - plications, s作者: 羞辱 時(shí)間: 2025-3-24 08:54
W. Hiddemann,K. Becker,A. Grote-Metke,R. Kuse,A. Bartholom?us,A. Reichle,I. Meuthen,D. K. Hossfeld,Tes needs beyond the stream processing model.Discusses in detIn recent years, a new class of applications has come to the forefront { p- marily due to the advancement in our ability to collect data from multitudes of devices, and process them e ciently. These include homeland security - plications, s作者: 現(xiàn)實(shí) 時(shí)間: 2025-3-24 14:09 作者: 注意到 時(shí)間: 2025-3-24 18:14 作者: enhance 時(shí)間: 2025-3-24 20:52
http://image.papertrans.cn/n/image/665209.jpg作者: 擦掉 時(shí)間: 2025-3-25 00:12
https://doi.org/10.1007/978-3-642-75720-4Aclacinomycin A; Akute Leuk?mie; Myelodysplast; Onkologie; Syndrom作者: impaction 時(shí)間: 2025-3-25 05:33
978-3-540-52613-1Springer-Verlag Berlin Heidelberg 1990作者: 文字 時(shí)間: 2025-3-25 08:57
Aclarubicin in Single Agent and Combined Chemotherapy of Adult Acute Myeloid Leukemia,The present contribution summarizes the results of treating acute myeloid leukemia (AML) with aclarubicin (ACM) in three consecutive studies. Some of the results have recently been published elsewhere [1–3].作者: Engaged 時(shí)間: 2025-3-25 12:55 作者: mitral-valve 時(shí)間: 2025-3-25 19:09 作者: CAND 時(shí)間: 2025-3-25 22:32 作者: BYRE 時(shí)間: 2025-3-26 03:26 作者: mercenary 時(shí)間: 2025-3-26 05:32
Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A median survival times as compared to those with no change (NC) or progressive disease (PD): 22 months for responders, 3 months for nonresponders. Censored median survival was 22 months for RAEB, 14 months for RAEB-T, but only 2 months for secondary ANLL. Evaluation of risk factors gave evidence of a作者: FER 時(shí)間: 2025-3-26 10:10 作者: 滑稽 時(shí)間: 2025-3-26 16:33
bination with conventional or intermediate- dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable978-3-540-52613-1978-3-642-75720-4作者: cortisol 時(shí)間: 2025-3-26 17:07
New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia作者: Decibel 時(shí)間: 2025-3-26 22:01
New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia978-3-642-75720-4作者: 現(xiàn)存 時(shí)間: 2025-3-27 01:44 作者: HPA533 時(shí)間: 2025-3-27 05:41
J. M. Rowe,A. Y. C. Chang,J. M. Bennettsty at times. For most of these applications, Quality of Service (or QoS) requirements, such as response time, memory usage, and throughput are extremely important. These application requirements make it infeas978-1-4419-4373-6978-0-387-71003-7Series ISSN 1386-2944 作者: CRACY 時(shí)間: 2025-3-27 13:18 作者: Gyrate 時(shí)間: 2025-3-27 16:40
ions. Furthermore, the data arrival rates may uctuate over a period of time and may be bursty at times. For most of these applications, Quality of Service (or QoS) requirements, such as response time, memory usage, and throughput are extremely important. These application requirements make it infeas作者: 同步左右 時(shí)間: 2025-3-27 21:42
P. S. Mitrouions. Furthermore, the data arrival rates may uctuate over a period of time and may be bursty at times. For most of these applications, Quality of Service (or QoS) requirements, such as response time, memory usage, and throughput are extremely important. These application requirements make it infeas作者: overture 時(shí)間: 2025-3-28 00:58 作者: 鬼魂 時(shí)間: 2025-3-28 05:36
D. Lutz,O. Krieger,H. Kasparu,E. Fiedlerions. Furthermore, the data arrival rates may uctuate over a period of time and may be bursty at times. For most of these applications, Quality of Service (or QoS) requirements, such as response time, memory usage, and throughput are extremely important. These application requirements make it infeas作者: Offbeat 時(shí)間: 2025-3-28 09:34
